Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug

Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.

Leave a comment

Your email address will not be published. Required fields are marked *